Cover Image
市場調查報告書

生物相似藥單株抗體 (MAb)的全球市場預測 2017-2027年:Infliximab / Rituximab / Trastuzumab / Trastuzumab/ Adalimumab / Bevacizumab / Abciximab的生物相似藥

Global Biosimilar Monoclonal Antibodies Forecast 2017-2027: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

出版商 Visiongain Ltd 商品編碼 275993
出版日期 內容資訊 英文 204 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物相似藥單株抗體 (MAb)的全球市場預測 2017-2027年:Infliximab / Rituximab / Trastuzumab / Trastuzumab/ Adalimumab / Bevacizumab / Abciximab的生物相似藥 Global Biosimilar Monoclonal Antibodies Forecast 2017-2027: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab
出版日期: 2017年05月19日 內容資訊: 英文 204 Pages
簡介

預測全球生物相似藥單株抗體 (MAb) 市場,在2015年到2027年間將以23.8%的年複合成長率 (CAGR) 擴大。推算該市場規模到2020年將達42億美元,2027年將達79億美元。

本報告提供全球生物相似藥單株抗體 (MAb) 市場相關調查,提供市場預測,各子市場的收益預測,彙整上市·開發中的生物相似藥抗體收益預測,主要國家市場分析與預測,STEP分析及主要企業簡介等,為您概述為以下內容。

第1章 報告概要

第2章 簡介:生物相似藥單株抗體

  • 自然地抗體:免疫系統的關鍵
  • 從血清療法到單株抗體 (MAbs)
  • MAb人體化
  • 生技藥品和生物相似藥
  • 生物相似藥為何擁有高需求?
  • 生物相似藥開發檢討事項
  • 已經上市的生物相似藥單株抗體

第3章 生物相似藥單株抗體的全球市場預測

  • 目前全球生物相似藥單株抗體市場
  • 全球生物相似藥MAb市場:收益預測
  • 全球生物相似藥MAb市場‐各化合物:收益·市場佔有率預測
  • 全球生物相似藥MAb市場‐各化合物:收益預測
  • 生物相似藥MAb市場促進成長要素·抑制因素
  • 生物相似藥MAb市場阻礙成長要素

第4章 各生物相似藥MAb產品:上市藥·開發平台藥物

  • 上市的生物相似藥MAb
  • 開發平台生物相似藥

第5章 主要國家的生物相似藥單株抗體市場

  • 主要國家市場生物相似藥MAb情形如何?
  • 主要國家市場佔有率通過預測期間將如何變化?
  • 印度:目前生物藥物單克隆抗體的領先國家,但增長速度將會減緩
  • 俄羅斯:缺乏法律規範的短期性順利
  • 韓國:受益於早期生物仿製藥指南
  • 中國:生物仿製藥市場細分化
  • 巴西:ANVISA的生物仿製藥法規與EMA相似
  • EU的生物相似藥MAb的展望
  • 日本的生物相似藥MAb的展望
  • 美國的生物相似藥MAb的展望

第6章 主要企業

  • 生物相似藥MAb開發的合作
  • BioXpress:以專利到期日為目標
  • Celltrion:企業的市場規模劇增到107億美元以上
  • Harvest Moon:6個化合物正在開發
  • Genor Biopharma:領導中國的生物相似藥MAb的市場
  • Samsung Bioepsis
  • Mabion:波蘭的主要生物相似藥MAb開發企業
  • Gene Techno Science:持續性的收益擴大
  • 印度的Biocon
  • Coherus Biosciences
  • BIOCAD:生物相似藥 Rituximab 銷售額的全球領導者
  • 大企業和生物相似藥MAb市場
  • 生物相似藥MAb市場上關注的收購

第7章 生物相似藥單株抗體市場定性分析

  • 優勢和弱點
  • 機會及威脅
  • 生物相似藥MAb影響市場的社會,技術,經濟及政治要素 (STEP分析)

第8章 結論

  • 生物相似藥單株抗體:全球市場
  • 市場·開發平台的化合物的未來
  • 主要國家市場
  • 主要企業
  • 產業趨勢現況·預測

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0194

The global biosimilar monoclonal antibodies market is expected to grow at a CAGR of 9.6% in the second half of the forecast period. The market is expected to grow at a CAGR of 23.8% from 2015-2027. The market is estimated at $4.2bn in 2020 and $7.9bn in 2027.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 72 tables and 72 figures - all unavailable elsewhere.

The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Biosimilar Monoclonal Antibodies Market forecasts from 2017-2027
  • Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2027 for the market segmented by compound:
    • Infliximab
    • Rituximab
    • Abciximab
    • Trastuzumab
    • Adalimumab
    • Bevacizumab
  • This report also shows revenue to 2027 for individual biosimilar mAb products in the market:
    • Remsima/Inflectra
    • Infimab
    • Reditux
    • BI695500
    • CT-P10
    • BI695501
    • FKB327
    • FKB238
    • Mabtas
    • AcellBia
    • Maball
    • Clotinab
    • Abcixirel
    • BCD-022
    • BCD-021
    • Herzuma
    • CANMAB/Hertraz
  • Our analyses show individual revenue forecasts to 2027 for these regional and national markets:
    • The US Biosimilar mAb Market
    • Japanese Biosimilar mAb Market
    • EU5 Biosimilar mAb Markets
    • BRIC and South Korea Biosimilar mAb Markets
    • Rest of the World Biosimilar mAb Market
  • This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline
  • Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market

Visiongain's study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.

Buy our report today Global Biosimilar Monoclonal Antibodies Forecast 2017-2027: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of Biosimilar Monoclonal Antibodies: R&D, Industry and Market
  • 1.2. Why You Should Read this Report
  • 1.3. How This Study Delivers
  • 1.4. Main Questions Answered by the Analysis
  • 1.5. Who is This Investigation For?
  • 1.6. Method of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQs)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to Biosimilar Monoclonal Antibodies

  • 2.1. Natural Antibodies: Key to the Immune System
  • 2.2. From Serum therapy to Monoclonal Antibodies
  • 2.3. Humanising the mAb
  • 2.4. Biologics (Biological Drugs) and Biosimilars
  • 2.5. Why are Biosimilars in High Demand?
  • 2.6. Considerations for the Development of Biosimilars
    • 2.6.1. Biologics and Biosimilars Are Large, Complex Molecules
    • 2.6.2. How Much of a Concern is Immunogenicity?
  • 2.7. Biosimilar Monoclonal Antibodies Currently on the Market

3. The Global Market for Biosimilar Monoclonal Antibodies, 2016-2027

  • 3.1. The Present Global Market for Biosimilar Monoclonal Antibodies
  • 3.2. The Global Market for Biosimilar mAbs: A Revenue Forecast, 2016-2027
  • 3.3. The Global Market for Biosimilar mAbs by Compound: Predictions for Revenue and Market Share in 2020 and 2027
  • 3.4. The World Market for Biosimilar mAbs by Compound: Revenue Forecasts, 2016-2027
    • 3.4.1. Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
    • 3.4.2. Biosimilar Infliximab: Currently the Second Largest Submarket
      • 3.4.2.1. Biosimilar Infliximab Revenue Forecast 2016-2027
    • 3.4.3. Biosimilar Rituximab: The Current Leading Submarket Driven by Sales in Russia
      • 3.4.3.1. Biosimilar Rituximab: Revenue Forecast 2016-2027
    • 3.4.4. Biosimilar Abciximab: Revenue Forecast 2016-2027
      • 3.4.4.1. Biosimilar Abciximab: Revenue Forecast, 2016-2027
    • 3.4.5. Biosimilar Trastuzumab: Pipeline Rich in Phase III Candidates
      • 3.4.5.1. Biosimilar Trastuzumab: Revenue Forecast, 2016-2027
    • 3.4.6. Biosimilar Adalimumab: Patents Hold Back Revenue on a Large Pipeline
      • 3.4.6.1. Biosimilar Adalimumab: Revenue Forecast 2016-2027
    • 3.4.7. Biosimilar Bevacizumab: Will Late Entry to the Biosimilar mAb Market Restrict Revenue?
      • 3.4.7.1. Biosimilar Bevacizumab: Revenue Forecast, 2016-2027
  • 3.5. Drivers and Restraints for the Biosimilar mAb market 2016-2027
    • 3.5.1. Driving Factors of the Biosimilar mAb Market 2016-2027
  • 3.6. Restraining Factors of the Biosimilar mAb Market 2016-2027

4. Individual Biosimilar mAb Products: Marketed and Pipeline Drugs, 2016-2027

  • 4.1. Biosimilar mAbs on the Market in 2017
    • 4.1.1. Celltrion's Remsima/ Hospira's Inflectra. Egis' Flammegis (Infliximab): The First Official Biosimilar Monoclonal Antibody
      • 4.1.1.1. Remsima/Inflectra/Flammegis Revenue Forecast, 2016-2027
    • 4.1.2. Infimab (Infliximab): Launched a Quarter Ahead of Schedule
      • 4.1.2.1. Infimab Revenue Forecast ($m) 2016-2027
    • 4.1.3. Dr Reddy's Reditux (Rituximab): No Application for EU or US Approval
      • 4.1.3.1. Reditux Revenue Forecast, 2016-2027
    • 4.1.4. Intas Pharmaceuticals' Mabtas (Rituximab)
      • 4.1.4.1. Mabtas (Rituximab) Revenue Forecast 2016-2027
    • 4.1.5. AcellBia (Rituximab): Sales in Russia Generating Large Revenue Figures
      • 4.1.5.1. AcellBia Revenue Forecast 2016-2027
    • 4.1.6. MABALL: Faces Competition from other Biosimilar Rituximabs in India
      • 4.1.6.1. MABALL Revenue Forecast, 2016-2027
    • 4.1.7. Isu Abxis' Clotinab (abciximab):
      • 4.1.7.1. Clotinab Revenue Forecast, 2016-2027
    • 4.1.8. AbcixiRel: The First Indian Abciximab Biosimilar
      • 4.1.8.1. AbcixiRel Revenue Forecast 2016-2027
    • 4.1.9. Herzuma (Trastuzumab): Approved in South Korea
      • 4.1.9.1. Herzuma Revenue Forecast 2016-2027
    • 4.1.10. CANMAb/Hertraz (Trastuzumab)
      • 4.1.10.1. CANMAb/Hertraz Revenue Forecast, 2016-2027
  • 4.2. Pipeline Biosimilars
    • 4.2.1. BI695500 (Rituximab): An EU Launch Anticipated in 2017
      • 4.2.1.1. BI695500 Revenue Forecast, 2016-2027
    • 4.2.2. CT-P10 (Rituximab): Celltrion's Reputation for Biosimilars will Assist Sales
      • 4.2.2.1. Celltrion's CT-P10 (Rituximab) Revenue Forecast, 2016-2027
    • 4.2.3. Boehringer Ingelheim's BI695501 (Adalimumab)
      • 4.2.3.1. BI695501 Revenue Forecast, 2016-2027
    • 4.2.4. BCD-022 (Trastuzumab): Currently under Development in Russia Only
      • 4.2.4.1. BCD-022 Revenue Forecast, 2016-2027
    • 4.2.5. Fujifilm Kyowa Kirin Biologics' FKB327 (Adalimumab)
      • 4.2.5.1. FKB327 Revenue Forecast, 2016-2027
    • 4.2.6. Fujifilm Kyowa Kirin Biologics' FKB238 (Bevacizumab)
      • 4.2.6.1. Fujifilm Kyowa Kirin Biologics' FKB238 Revenue Forecast 2016-2027
    • 4.2.7. BCD-021 (Bevacizumab): Russia Will Contribute the Most Revenue
      • 4.2.7.1. BCD-021 Revenue Forecast 2016-2027

5. Leading National Markets for Biosimilar Monoclonal Antibodies

  • 5.1. What Were the Leading National Markets for Biosimilar mAbs in 2016?
  • 5.2. How Will National Market Shares Change Over the Forecast Period?
  • 5.3. India: The Current Leading Nation for Biosimilar mAbs but Growth will Slow
    • 5.3.1. India Releases New Biosimilar Development Guidelines
    • 5.3.2. Indian Biosimilar Submarket Forecast 2016-2027
  • 5.4. Russia: Lack of Regulatory Framework Works Well in the Short Term
    • 5.4.1. Russian Government Backed ‘Pharma 2020' Initiative
    • 5.4.2. Russian Biosimilar mAb Revenue Forecast, 2016-2027
  • 5.4. South Korean Market has Benefitted from Early Biosimilar Guidelines
    • 5.4.1. Significant Investment in Biosimilars in South Korea
    • 5.4.2. South Korean Biosimilar mAb Revenue Forecast, 2016-2027
  • 5.5. China: A Fragmented Biosimilar mAb Market
    • 5.5.1. Chinese FDA Publishes Finalised Biosimilar Guidelines in 2015
    • 5.5.2. China Biosimilar mAb Revenue Forecast, 2016-2027
  • 5.6. Brazil: ANVISA's Biosimilar Regulations Are Similar the EMA's
    • 5.6.1. Brazil Biosimilar mAb Revenue Forecast 2016-2027
  • 5.7. The Outlook for Biosimilar mAbs in the EU 2016-2027
    • 5.7.1. Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar mAbs
    • 5.7.2. Biosimilar mAbs in the EU5: Revenue Forecasts, 2016-2027
    • 5.7.3. Germany: The Current EU Leader
    • 5.7.4. France: Will the Uptake of Biosimilar mAbs be Restricted?
    • 5.7.5. UK: NICE Recommends Use of Remsima for Certain Indications
    • 5.7.6. Italy: Healthcare Spending Cuts Will Drive Growth
    • 5.7.7. Spain: High Biosimilar mAb Discounts Expected
  • 5.8. The Outlook for Biosimilar mAbs in Japan
    • 5.8.1. Regulations for Naming Biosimilars
    • 5.8.2. Biosimilar mAb Market Activity in Japan
    • 5.8.3. Japanese Biosimilar Submarket Forecast 2016-2027
  • 5.9. US Biosimilar mAb Outlook: None Currently on the Market
    • 5.9.1. US FDA Biosimilar Guidelines were Released in 2015
    • 5.9.2. Legal Challenges for Biosimilars in the US
    • 5.9.3. State Regulation of Biosimilar Substitution
    • 5.9.4. The US Biosimilar mAb Market Revenue Forecast, 2015-2027

6. Leading Companies in the Biosimilar Monoclonal Antibodies Market

  • 6.1. Collaboration in Biosimilar mAb Development
  • 6.2. BioXpress: Targeting Patent Expiry Dates in 2019-2023
  • 6.3. Celltrion: Company's Market Value Surges to Exceed $10.7bn
  • 6.4. Harvest Moon: Six Compounds Under Development
  • 6.5. Genor Biopharma: A Biosimilar mAb Market Leader in China
  • 6.6. Samsung Bioepsis
  • 6.7. Mabion: Poland's Leading Biosimilar mAb Developer
  • 6.8. Gene Techno Science: Substantial Revenue Increases Since 2014
  • 6.9. India's Biocon:
  • 6.10. Coherus Biosciences
  • 6.11. BIOCAD: World Leader Biosimilar Rituximab Sales
  • 6.12. Big Pharma and the Biosimilar mAb Market
  • 6.13. Significant Acquisitions in the Biosimilar mAb Market
    • 6.13.1. Pfizer Acquires Hospira
    • 6.13.2. Epirus Acquires Bioceros

7. Qualitative Analysis of Biosimilar Monoclonal Antibodies Market

  • 7.1. Strengths and Weaknesses of the Biosimilar Monoclonal Antibodies Market, 2016-2027
    • 7.1.1. Global Demand for Affordable Biopharmaceuticals has Never Been Greater
    • 7.1.2. Adoption of Biosimilar mAbs will be Proportional to the Rate of Discount
    • 7.1.3. Approval Pathways are Now Established in Developed Markets
    • 7.1.4. Complexity of Protein Molecules Leads to Technical Challenges
    • 7.1.5. Doctor and Patient Confidence May Take Time
  • 7.2. Opportunities and Threat Facing the Biosimilar Monoclonal Antibodies Market, 2016-2027
    • 7.2.1. Market Opportunities from Patent Expiries and a Well-stocked Pipeline
    • 7.2.2. Substitution may Not Occur Automatically
    • 7.2.3. Biobetters Offer a Serious Threat to the Production and Uptake of Biosimilars
  • 7.3. Social and Technological Forces Influencing the Biosimilar Monoclonal Antibodies Market 2016-2027
    • 7.3.1. Social Factors: Driving or Restraining the Market?
    • 7.3.2. Technological Factors Concentrate on Reducing Costs and Increasing Ease of Production
    • 7.3.3. Economic Pressures Raise Demand for Biosimilar mAbs
      • 7.3.3.1. Fragmentation of the Market Could Limit Individual Drug Revenues
    • 7.3.4. Political Issues: Stringent Regulations Hurdles to Market Entry

8. Conclusions

  • 8.1. Biosimilar Monoclonal Antibodies: World Market, 2016-2027
  • 8.2. Future of Compounds on the Market and in the Pipeline
  • 8.3. Leading National Markets for Biosimilar Monoclonal Antibodies 2016-2027
  • 8.4. Leading Companies in the Biosimilar mAb Market
  • 8.5. Current and Expected Industry Trends 2016-2027
    • 8.5.1. Cost Control of Healthcare Will Work in Favour mAbs
    • 8.5.2. Upcoming Patent Expiries in Developed Markets Offer Large Market Potential
    • 8.5.3. Complex Production Processes are a Restraining Factor
    • 8.5.4. Clinician and Patient Confidence Must be Maximised to Ensure Uptake
    • 8.5.5. Biobetters Pose a Threat
  • Visiongain Report Sales Order Form
  • Associated Visiongain Reports
  • About Visiongain
  • Visiongain report evaluation form

List of Figures

  • Figure 1.1: Main Compound Classes of Biosimilar mAbs, 2017
  • Figure 2.1: Structure of an Antibody
  • Figure 3.1: Global Market for Biosimilar mAbs: Revenue forecast ($m), 2016-2027
  • Figure 3.2: The Biosimilar mAb Market: Market Share (%) by compound in 2017
  • Figure 3.3: The Biosimilar mAb Market: Market Share (%) by compound in 2020
  • Figure 3.4: The Biosimilar mAb Market: Market Share (%) by compound in 2027
  • Figure 3.5: Biosimilar Infliximab: Global Revenue ($m) Forecast 2016-2027
  • Figure 3.6: Biosimilar Rituximab: Global Revenue ($m) Forecast 2016-2027
  • Figure 3.7: Biosimilar Abciximab: Global Revenue ($m) Forecast 2016-2027
  • Figure 3.8: Biosimilar Trastuzumab: Global Revenue ($m) Forecast 2016-2027
  • Figure 3.9: Biosimilar Adalimumab: Global Revenue ($m) Forecast 2016-2027
  • Figure 3.10: Biosimilar Bevacizumab: Global Revenue ($m) Forecast 2016-2027
  • Figure 3.11: Drivers and Restraints for the Global Biosimilar mAb market 2016-2027
  • Figure 4.1: Biosimilar mAb Versions on the Market: Market Share (%) 2017
  • Figure 4.2: Biosimilar mAb Versions on the Market: Market Share (%) 2020
  • Figure 4.3: Biosimilar mAb Versions on the Market: Market Share (%) 2027
  • Figure 4.4: Remsima/Inflectra/Flammegis (Infliximab): Revenue Forecast ($m), 2016-2027
  • Figure 4.5: Remsima/Inflectra/Flammegis (Infliximab): AGR Forecast (%), 2016-2027
  • Figure 4.6: Infimab (Infliximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.7: Infimab (Infliximab): AGR Forecast (%) 2016-2027
  • Figure 4.8: Reditux (Rituximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.9: Reditux (Rituximab): AGR Forecast (%) 2016-2027
  • Figure 4.10: Mabtas (Rituximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.11: Mabtas (Rituximab): AGR Forecast (%) 2016-2027
  • Figure 4.12: AcellBia (Rituximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.13: AcellBia (Rituximab): AGR Forecast(%) 2016-2027
  • Figure 4.14: MABALL (Rituximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.15: MABALL (Rituximab): AGR Forecast(%) 2016-2027
  • Figure 4.16: Clotinab (Abciximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.17: Clotinab (Abciximab): AGR Forecast (%) 2016-2027
  • Figure 4.18: AbcixiRel (Abciximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.19: AbcixiRel (Abciximab): AGR Forecast (%) 2016-2027
  • Figure 4.20: Herzuma (Trastuzumab): Revenue Forecast ($m) 2016-2027
  • Figure 4.21: Herzuma (Trastuzumab): AGR Forecast (%) 2016-2027
  • Figure 4.22: CANMAb/Hertraz (Trastuzumab): Revenue Forecast ($m) 2016-2027
  • Figure 4.23: CANMAb/Hertraz (Trastuzumab): AGR Forecast (%) 2016-2027
  • Figure 4.24: BI695500 (Rituximab): Revenue Forecast ($m) 2017-2027
  • Figure 4.25: BI695500 (Rituximab): AGR Forecast (%) 2018-2027
  • Figure 4.26: CT-P10 (Rituximab): Revenue Forecast ($m) 2018-2027
  • Figure 4.27: CT-P10 (Rituximab): AGR Forecast (%) 2019-2027
  • Figure 4.28: BI695501 (Adalimumab): Revenue Forecast ($m) 2017-2027
  • Figure 4.29: BI695501 (Adalimumab): AGR Forecast (%)2018-2027
  • Figure 4.30: BCD-022 (Trastuzumab): Revenue Forecast ($m) 2016-2027
  • Figure 4.31: BCD-022 (Trastuzumab): AGR Forecast (%) 2017-2027
  • Figure 4.32: FKB327 (Adalimumab): Revenue Forecast ($m) 2017-2027
  • Figure 4.33: FKB327 (Adalimumab): AGR Forecast (%) 2018-2027
  • Figure 4.34: FKB238 (Adalimumab): Revenue Forecast ($m) 2020-2027
  • Figure 4.35: FKB238 (Adalimumab): AGR Forecast(%) 2021-2027
  • Figure 4.36: BCD-021 (Bevacizumab): Revenue Forecast ($m) 2017-2027
  • Figure 4.37: BCD-021 (Bevacizumab): AGR Forecast (%) 2018-2027
  • Figure 5.1: The Biosimilar MAb Market by Country: Market Shares (%) of Revenue, 2016
  • Figure 5.2: The Biosimilar MAb Market: National Submarket Shares (%), 2020
  • Figure 5.3: The Biosimilar MAb Market: National Submarket Shares (%), 2027
  • Figure 5.4: The Indian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.5: The Russian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.6: The South Korean Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.7: The Chinese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.8: The Brazilian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.9: The EU5 Biosimilar mAb Market: Grouped Revenue Forecast ($m), 2016-2027
  • Figure 5.10: The EU5 Biosimilar mAb Market: Revenue Forecasts ($m) by Country, 2016-2027
  • Figure 5.11: The German Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.12: The French Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.13: The UK Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.14: The Italian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.15: The Spanish Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.16: The Japanese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.17: Biosimilar mAbs in the US: Revenue Forecast ($m), 2017-2027
  • Figure 6.1: Prominent Companies in the Biosimilar mAb Industry: Share (%) of the Pipeline,
  • Figure 8.1: Prominent Compounds in the Biosimilar mAb Market: Comparison of Revenues ($m), 2017, 2020 and 2027
  • Figure 8.2: Forecasted Biosimilar mAbs: Comparison of Revenues ($m), 2017, 2020 and 2027
  • Figure 8.3: Leading National Markets: Revenues ($m), 2017, 2020 and 2027
  • Figure 8.4: Prominent Companies in the Biosimilar mAb Industry: Number of Products in Current Development or in the Pipeline, 2017

List of Tables

  • Table 1.1: Biosimilar mAbs: Global Revenue Forecast by Reference Compound 2016-2027
  • Table 2.1: Classification of Monoclonal Antibodies
  • Table 2.2: Murine Monoclonal Antibodies on the Market, 2017
  • Table 2.3: Chimeric Monoclonal Antibodies on the Market, 2017
  • Table 2.4: Humanised Monoclonal Antibodies on the Market, 2017
  • Table 2.5: Fully Human Monoclonal Antibodies on the Market, 2017
  • Table 2.6: Revenue of Originator Monoclonal Antibody Products in 2016
  • Table 3.1: Biosimilar mAb Global Market: Revenue Forecast ($m), 2016-2027
  • Table 3.2: Global Market for Biosimilar mAbs: Revenues ($m) and Market Shares (%) by Reference Compound, 2017, 2020 and 2027
  • Table 3.3: EU and US Patent Expiry Dates for the Main mAb Reference Products
  • Table 3.4: Biosimilar mAbs: Global Revenue Forecast by Reference Compound 2016-2027
  • Table 3.5: Biosimilar Infliximab: Compounds Awaiting Approval in the Pipeline
  • Table 3.6: Biosimilar Infliximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
  • Table 3.7: Biosimilar Rituximab: Compounds Marketed and in the Pipeline, 2017
  • Table 3.8: Biosimilar Rituximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
  • Table 3.9: Biosimilar Abciximab: Compounds Marketed and in the Pipeline, 2016
  • Table 3.10: Biosimilar Abciximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
  • Table 3.11: Biosimilar Trastuzumab: Compounds Marketed and in the Pipeline, 2017
  • Table 3.12: Biosimilar Trastuzumab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
  • Table 3.13: Biosimilar Adalimumab: Compounds Marketed and in the Pipeline, 2017
  • Table 3.14: Biosimilar Adalimumab: Global Revenue Forecast 2016-2027
  • Table 3.15: Biosimilar Bevacizumab: Compounds Marketed and in the Pipeline, 2017
  • Table 3.16: Biosimilar Bevacizumab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
  • Table 4.1: Biosimilar mAbs on the Market in 2017: Revenues ($m) and Market Shares (%)
  • Table 4.2: Remsima/Inflectra/Flammegis (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.3: Infimab (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.4: Reditux (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.5: Mabtas (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.6: Biocad Distribution Partners for AcellBia, 2016
  • Table 4.7: AcellBia (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.8: MABALL (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.9: Clotinab (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.10: AbcixiRel (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.11: Herzuma (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.12: CANMAb/Hertraz (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.13: BI695500 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 4.14: CT-P10 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2018-2027
  • Table 4.15: BI695501 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 4.16: BCD-022 (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.17: FKB327 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 4.18: FKB238 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2020-2027
  • Table 4.19: BCD-021 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 5.1: Leading National Markets for the Global Biosimilar mAb Industry, 2016
  • Table 5.2: Leading National Markets for the Global Biosimilar mAb Industry, 2016-2027
  • Table 5.3: The Indian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.4: The Russian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.5: The South Korean Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.6: The Chinese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.7: The Brazilian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.8: The EU5 Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Table 5.9: The German Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.10: The French Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.11: The UK Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.12: The Italian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.13: The Spanish Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.14: The Japanese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.15: Finalised FDA Biosimilar Guidelines, 2015
  • Table 5.16: The US Biosimilar mAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2017-2027
  • Table 6.1: Companies in the Biosimilar mAb Industry by Number of Compounds in Development, 2017
  • Table 6.2: Selected Collaborations for Biosimilar mAb Development, 2009-2017
  • Table 6.3: BioXpress: Compounds in the Pipeline, 2017
  • Table 6.4: Tests Carried Out By BioXpress During Biosimilar mAb Development, with Objectives
  • Table 6.5: Compounds in Celltrion's Pipeline: Compound Name, Generic Name, Development Stage and Anticipated Year of Approval, 2017
  • Table 6.6: Genor Biopharma: Biosimilar mAbs Pipeline, 2017
  • Table 6.7: Mabion: Compounds in the Pipeline and Their Development Stage, 2017
  • Table 6.8: Gene Techno Science: Revenue ($m), from 2013-2017
  • Table 6.9: Biocon: Compounds in the Pipeline and Their Stage of Development, 2017
  • Table 6.10: Big Pharma's Positions in the Biosimilar mAb Industry, 2017
  • Table 6.11: Significant Acquisitions in the Biosimialr mAb Market 2017
  • Table 7.1: Strengths and Weaknesses of the Biosimilar mAb Market, 2016-2027
  • Table 7.2: Opportunities and Threats Facing the Biosimilar mAb Market, 2016-2027
  • Table 7.3: Social and Technological Factors Influencing the Biosimilar mAb Market, 2016-2027

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • Aché
  • Actavis
  • AET BioTech
  • Alexion Pharmaceuticals
  • Alvogen
  • Alvotech
  • Amgen
  • Aprogen
  • Array Bridge
  • AstraZeneca
  • Bayer
  • Binex
  • BIO
  • BIOCAD
  • Biocerus
  • Biocon
  • Biogen Idec
  • Bio-Manguinhos
  • Bionovis
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cell Therapeutics
  • Celltrion
  • Celon Pharma Lomianki
  • CinnaGen
  • Coherus BioSciences
  • Daiichi Sankyo
  • Dong-A
  • Dr. Reddy's Laboratories
  • Egis Pharmaceuticals
  • Eli Lilly
  • Emcure
  • EMS
  • Epirus Biopharmaceuticals
  • Farmasa
  • Fresenius
  • Fujifilm Kyowa Kirin Biologics
  • Gedeon Richter
  • Gene Techno Science
  • Genentech
  • Genexo
  • Genor Biopharma
  • GlaxoSmithKline (GSK)
  • Glycotope
  • Hanwha Chemical
  • Harvest Moon
  • Hospira
  • Hypermarcas
  • iBio
  • IBSS Biomed
  • ImClone LLC
  • Instas Pharmaceuticals
  • Instituto Vital Brazil
  • IPCA Labs
  • Isu Abxis
  • Janssen
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Laboratorios Liomont
  • LG Life Sciences
  • Lonza
  • Mabion
  • mAbxience
  • MedImmune
  • Merck & Co.
  • Merck Serono
  • Millhouse LLC
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Mustafa Nevzat Pharmaceuticals
  • Mylan
  • Natco Pharma
  • Nichi-Iko Pharmaceutical Co.
  • Nippon Kayaku
  • Novartis
  • Oncobiologics
  • Otsuka Pharmaceutical
  • Parexel
  • Pfizer
  • PharmaPraxis
  • Pharmstandard
  • PhRMA
  • PlantForm
  • Polfarmex
  • Probiomed
  • QuantiaMD
  • Quintiles
  • Reliance Life Sciences
  • Roche
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Schnell
  • Seattle Genetics
  • Shanghai CP Guojian
  • Shionogi
  • Sorrento
  • Spectrum Pharmaceuticals
  • Stada
  • Synthon
  • Takeda
  • Teva Pharmaceutical Industries
  • UCB
  • União Química
  • Viropro
  • Walvax Biotechnology
  • Wyeth
  • Zenotech
  • Zhejiang Huahai Pharmaceutical

Organizations Mentioned in the Report

  • Agence française de sécurité sanitaire des produits de santé (ANSM)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Chinese Centre for Drug Evaluation (CDE)
  • Cour des Comptes (France)
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • Fraunhofer Center for Molecular Biology
  • Health Canada
  • India Brand Equity Foundation
  • Korean Food and Drug Administration (KFDA)
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Ministry of Food and Drug Safety (South Korea)
  • Ministry of Health (Russia)
  • Ministry of Health, Labour and Welfare (MHLW)
  • National Institute for Health and Care Excellence (NICE)
  • National Institute for Health Research Horizon Scanning Centre
  • Norwegian Medical Agency
  • Russian Ministry of Health
  • Scientific Centre for Expertise of Medicinal Application Products (Russia)
  • Spanish Ministry of Health
  • State Food and Drug Administration (SFDA)
  • The Cancer Centre Bahamas
  • Washington Legal Foundation
  • World Health Organization (WHO)
Back to Top